https://endpts.com/analyst-pens-a-barbed-note-to-biogen-shed-caution-dump-alzheimers-and-retool-at-the-top-go-bold/

Apparently Biogen is taking heat, not only for aducanuma's failure and the lack of other late stage compounds in the development pipeline, but also for announcing a $5 billion share buyback after the phase 3 failure which is on top of an already announced buyback of over $1 billion.

Analysts are apparently reccomending an agressive M&A strategy......